AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2015
Sep 3, 2015
29977_dirs_2015-09-03_9f0ae4b4-0a1e-4712-a55d-df6c281bdb83.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2015-09-02
Reporting Person: SCHLEIFER LEONARD S (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-09-02 | Common Stock | M | 7226.0 | $402.69 | Acquired | 49313 | Direct |
| 2015-09-02 | Common Stock | F | 5745.0 | $506.37 | Disposed | 43568 | Direct |
| 2015-09-02 | Common Stock | F | 762.0 | $506.37 | Disposed | 42806 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-09-02 | Non-Qualified Stock Option (right to buy) | $402.69 | M | 7226.0 | Disposed | 2015-12-19 | Common Stock (7226) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5681 | Indirect |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Earnings Release
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Earnings Release
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3